Litigation

Helsinn Healthcare S.A. v. Mylan Inc. et al.

settled/terminated

1:14-cv-00709

Filed
2014-06-04
Terminated
2015-10-05

Patents at issue (1)

7947725

Summary

D. Del. action asserting the '725 patent against Mylan. Settled/terminated.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Case Overview — Helsinn Healthcare S.A. v. Mylan Inc., No. 1:14-cv-00709-GMS (D. Del.)

Parties. Helsinn Healthcare S.A. is a Swiss specialty pharmaceutical company (Lugano) that owns NDA No. 021372 for Aloxi® (palonosetron hydrochloride injection), approved July 25, 2003, and it asserted the Orange Book patents covering that product. It was joined by Roche Palo Alto LLC (a Delaware corporation with its principal place of business in Palo Alto, California — successor to Syntex), which had discovered/developed palonosetron and licensed the compound and related IP to Helsinn in 1998; the patents-in-suit are jointly assigned to Helsinn and Roche Palo Alto. Helsinn is a practicing, product-based plaintiff, not an NPE/PAE — Stanford's NPE Litigation Database codes Helsinn in this case as a "product company." The defendants were Mylan Inc., the global generics parent, and Mylan Institutional LLC, a Delaware LLC (Rockford, Illinois) that is Mylan's institutional/unit-dose generics arm and the entity that filed the ANDA. Mylan Inc. immediately moved to dismiss for lack of personal jurisdiction (D.I. 9–10, filed June 26, 2014); the litigation thereafter proceeded against Mylan Institutional and was ultimately dismissed only "as to Mylan Institutional LLC" (D.I. 37), which implies Mylan Inc. was dropped earlier, though I could not locate the specific order in the public docket excerpts reviewed. Docket via CourtListener/UniCourt; Hospira opinion describing Helsinn/Roche corporate roles

Accused product and patents. The accused conduct is Mylan's submission of an ANDA under 35 U.S.C. § 271(e)(2) seeking approval to market generic palonosetron hydrochloride injection in the Aloxi strengths — 0.25 mg (base)/5 mL and 0.075 mg (base)/1.5 mL single-use vials — with Paragraph IV certifications that the patents are invalid, unenforceable, and/or not infringed. The complaint (filed June 4, 2014) asserted five Orange Book patents: the '725 patent (U.S. 7,947,725, "Liquid Pharmaceutical Formulations of Palonosetron," issued May 24, 2011 from Appl. 11/388,268, claiming a stable injectable solution of 0.03–0.2 mg/mL palonosetron HCl, pH 4–6, tonifying mannitol, and 0.005–1.0 mg/mL EDTA — claim 2 being the 0.05 mg/mL, pH 4.5–5.5, EDTA + mannitol embodiment); the sibling '724 and '424 patents (same specification/priority, different claim scope); the '219 patent (fixed 0.25 mg dose in 5 mL); and the '094 patent, added after it issued May 20, 2014 (Mylan served a supplemental Paragraph IV notice as to the '094 on June 27, 2014). The whole family descends from PCT/EP2004/000888 (Jan. 30, 2004) with a Jan. 30, 2003 priority date, and all carried an Orange Book expiry of January 30, 2024 (July 30, 2024 with pediatric exclusivity). [DrugPatentWatch case record listing all five patents](https://www.drugpatentwatch.com/p/l

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Key finding: this case was consolidated into lead D. Del. No. 13-688 (Helsinn v. Cipla) in Nov. 2014. Let me pull the full docket and the consolidation order, plus check for IPRs on the '725.

Now let me get the full 14-709 docket and the Markman order, plus check for PTAB proceedings against Helsinn's palonosetron patents.

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Good leads. Let me pull the actual complaint and docket documents.

The complaint appears to have two plaintiffs. Let me verify by pulling the actual docket and complaint.

Counsel of Record — Plaintiffs, Helsinn Healthcare S.A. v. Mylan Inc., No. 1:14‑cv‑00709‑GMS (D. Del.)

Preliminary correction to the record: the public docket and complaint show two plaintiffs — Helsinn Healthcare S.A. and Roche Palo Alto LLC (Roche Palo Alto appears as a "Counter‑Defendant" in the attorney listing because Mylan counterclaimed against both). The case metadata lists only Helsinn. Likewise, the docket/case databases reflect assertion of the '724, '725, '424, '219 and '094 patents in this action, not the '725 alone. (FJC IDB record; UniCourt docket extract; Google Patents' reproduction of the 14‑709 complaint, cited in US 9,457,021)

Attorneys appearing for plaintiffs on this docket

Attorney Role Firm / Office Note
Jack B. Blumenfeld (D. Del. Bar #1014) Lead Delaware counsel of record Morris, Nichols, Arsht & Tunnell LLP, 1201 N. Market St., Wilmington, DE Dean of the Delaware patent bar; perennial local/lead counsel in Hatch‑Waxman ANDA cases (e.g., AstraZeneca, Forest Labs v. Mylan matters). Signed plaintiffs' Claim Construction Chart here (D.I. 32, 10/24/2014).
Maryellen Noreika (D. Del. Bar #3208) Delaware counsel of record (co‑counsel on all plaintiff filings) Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE Filed plaintiffs' first interrogatories/RFP (D.I. 29), plaintiffs' proposed claim constructions (D.I. 31), and the stipulation of dismissal (D.I. 37, 9/30/2015). Later confirmed as a U.S. District Judge for the District of Delaware (2021), i.e., she now sits on the very court where she appeared.

Both are listed on the docket as "Counter Defendant Attorneys" for Helsinn and Roche Palo Alto, and their signature blocks appear as "Attorneys for Plaintiffs Helsinn Healthcare S.A. and Roche Palo Alto LLC" — e.g., the consolidated claim‑construction briefing in the lead case, C.A. No. 13‑688‑GMS, D.I. 119 (12/5/2014) (PDF).

What I could not verify — stated explicitly

  • No national/lead trial firm (e.g., Finnegan, or any out-of-state firm) appears in the publicly indexed attorney list for this docket. The only plaintiff-side attorneys returned by the docket databases are Blumenfeld and Noreika. It is entirely possible that Helsinn's outside patent counsel from a Washington/D.C. or New Jersey firm worked behind the scenes and/or was admitted pro hac vice in the lead consolidated case, C.A. No. 13‑688‑GMS, without a separate appearance here. This short-lived case (consolidated in Nov. 2014, dismissed in Oct. 2015) does not, on the accessible record, contain a pro hac vice motion for any plaintiff-side attorney. I am therefore not naming a national-firm lead counsel — I have no sourced basis to do so, and I will not guess.
  • No in-house counsel for Helsinn or Roche Palo Alto appears on the docket.

Procedural context relevant to who was counsel "of record"

  • D.I. 1 — Complaint filed 6/4/2014 (Helsinn + Roche Palo Alto v. Mylan Inc. and Mylan Institutional LLC).
  • D.I. 9–10 — Mylan Inc.'s motion to dismiss for lack of personal jurisdiction and sealed opening brief (6/26/2014).
  • D.I. 35–36 — Joint status report and Sleet, J. order (11/10/2014) consolidating and directing that "ALL FUTURE FILINGS SHALL BE MADE ONLY IN LEAD CA 13‑688 GMS" — after which plaintiffs' counsel of record in practice was the same Morris Nichols team litigating the consolidated ALOXI® ANDA cases.
  • D.I. 37–38 — Stipulation of dismissal as to Mylan Institutional LLC (filed by Noreika, 9/30/2015) and Rule 77 report to the Patent Office (10/5/2015), matching the FJC termination date of Oct. 5, 2015 and disposition "Settled."

Sourcing caveat: the above is drawn from the FJC IDB/CourtListener docket record, a UniCourt docket transcription, and filed PDFs hosted on CourtListener. I did not have direct PACER access to the 14‑709 docket sheet itself; if you need certainty on pro hac vice admissions, the PACER docket for 1:14‑cv‑00709 and 1:13‑cv‑00688 should be pulled directly.

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Let me pull the actual docket and filings for this specific case.

Now let me verify firms and roles for each name on the docket.

Counsel of Record — Defendants Mylan Inc. and Mylan Institutional LLC

Helsinn Healthcare S.A. v. Mylan Inc., No. 1:14-cv-00709-GMS (D. Del.)

Sourcing note up front: I could not query PACER directly in this session. The identification below rests on the CourtListener RECAP docket for this case (Docket No. 13252243, Helsinn Healthcare SA v. Mylan Institutional LLC, D. Del. 1:14-cv-00709), including the docket text of the pro hac vice admission minute entry of 11/04/2014, plus a UniCourt docket mirror and firm/press sources for biographical detail. Attorneys whose names appear only in aggregator "attorney" lists (not tied to a filing I could read) are flagged as unverified rather than presented as confirmed.

Confirmed appearances on this docket

Attorney Role Firm / Office Note
David Ellis Moore Delaware counsel (local) — principal filer for Mylan Institutional LLC Potter Anderson & Corroon LLP, Wilmington, DE Delaware IP litigator who regularly serves as local counsel in Hatch-Waxman/ANDA actions in D. Del.; filed Mylan's Rule 26 disclosures and discovery papers here (e.g., D.I. 34, 11/04/2014). (Firm affiliation is from longstanding public record; firm website not re-verified this session.)
Bindu Ann George Palapura Delaware counsel (local) Potter Anderson & Corroon LLP, Wilmington, DE Filed Mylan Institutional LLC's interrogatory/document responses and proposed claim constructions (D.I. 30, 33). Same Delaware Hatch-Waxman local-counsel practice as Moore.
George J. Barry III Lead national/trial counsel (pro hac vice) McGuireWoods LLP — Atlanta, GA Entered pro hac vice for Mylan Institutional LLC per the 11/04/2014 minute entry; longtime ANDA/Hatch-Waxman defense counsel for generic sponsors, including Mylan.
Cedric C. Y. Tan National counsel (pro hac vice) McGuireWoods LLP — Washington, D.C. Admitted pro hac vice 11/04/2014. Life-sciences patent litigator who joined McGuireWoods in July 2014 from Crowell & Moring; practice focused on Hatch-Waxman generic-pharma litigation and, later, BPCIA/biosimilars disputes (confirmed by CDR News and IP Today coverage of his move).
Brie L.B. Buchanan National counsel / associate (pro hac vice) McGuireWoods LLP — Atlanta, GA Admitted pro hac vice 11/04/2014 alongside Barry and Tan. Firm/office attribution is from the McGuireWoods Mylan team in this era; lower confidence than Barry/Tan — treat office location as unverified.
Richard L. Horwitz Delaware counsel on Mylan's counterclaims in the consolidated lead action Potter Anderson & Corroon LLP, Wilmington, DE Listed on the docket as counterclaimant's Delaware attorney; filed the 04/24/2015 pro hac vice motion for McGuireWoods' Michael F. Nullet in the lead consolidated case (C.A. 13-688).
Michael F. Nullet National counsel (pro hac vice, later appearance) McGuireWoods LLP Pro hac vice motion filed 04/24/2015 by Horwitz in the lead consolidated case, on behalf of Mylan Institutional LLC. Office location not verified.

Names I could not confirm (do not rely on without checking PACER)

UniCourt's attorney list for this docket also shows Erich William Struble, Micheal L. Binns, and Timothy H. Kratz as "Defendant Attorneys." I found no docket filing, opinion, or firm source tying any of them to an appearance in 1:14-cv-00709. Given that this action was consolidated into lead C.A. No. 13-688-GMS (D.I. 36, 11/10/2014) and that aggregator lists frequently bleed counsel across consolidated Helsinn/Aloxi cases, these are best treated as unverified — possibly counsel in a related Helsinn matter rather than this one.

Structural points worth noting

  • Only Mylan Institutional LLC appears to have litigated. The complaint named Mylan Inc. and Mylan Institutional LLC, but the appearances, discovery filings, and claim-construction papers in this docket run to Mylan Institutional LLC only. Mylan Inc.'s participation (e.g., whether it was dismissed early) is not something I could confirm from the materials retrieved.
  • The case was not tried. Judge Gregory M. Sleet entered an order (D.I. 36) directing that all future filings be made in lead C.A. No. 13-688-GMS; Helsinn then filed a stipulation of dismissal as to Mylan Institutional LLC (D.I. 37, 09/30/2015), with the Report to the Commissioner of Patents and Trademarks entered 10/05/2015 (D.I. 38) — matching the 2015-10-05 termination date in the case metadata.
  • No Mylan in-house attorney is identified as counsel of record on this docket.
  • No sealed counsel-related filings were encountered; however, D.I. 10 (Mylan's opening brief in support of a motion to dismiss for lack of personal jurisdiction, filed 06/26/2014) is docketed as sealed, and I did not read it, so I cannot state with certainty which defendant entity brought that motion.

Bottom line for citation purposes: If you need a clean, citable defense-side lineup for 1:14-cv-00709, use Potter Anderson & Corroon LLP (David E. Moore; Bindu A. G. Palapura; Richard L. Horwitz) as Delaware counsel and McGuireWoods LLP (George J. Barry III; Cedric C. Y. Tan; Brie L.B. Buchanan; later Michael F. Nullet) as pro hac vice national counsel — all four McGuireWoods PHV admissions being corroborated by the CourtListener docket entry of 11/04/2014.